Linked Life Data

16870552

Source:http://linkedlifedata.com/resource/pubmed/id/16870552

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2006-8-3
pubmed:abstractText
We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1592-8721
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1105-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
pubmed:affiliation
Division of Hematology, Mayo Clinic College of Medicine, 200 First St. S.W., Rochester, MN 55905, USA. litzow.mark@mayo.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Multicenter Study, Clinical Trial, Phase II, Research Support, N.I.H., Extramural